The global nucleic acid and oligonucleotide therapies industry has evolved significantly over the last few decades, reflecting advances in biotechnology and genomics. This market include medicines that use nucleic acids or oligonucleotides to treat genetic problems, cancer, and infections. This market's primary technologies are RNA interference (RNAi), antisense oligonucleotides (ASOs), and gene editing tools like CRISPR/Cas9. The early 2000s saw the start of a more targeted approach to creating nucleic acid-based medicines, fuelled by advances in sequencing technologies and a better knowledge of gene expression and control. The completion of the Human Genome Project in 2003 accelerated the discipline, paving the way for personalised medicine and targeted therapeutics. The EMA and other international regulatory agencies have created frameworks to help in the development and approval of these novel treatments, emphasising a balanced approach to regulatory control and scientific advancement. In the United States, the FDA has issued special guidance for RNA-based therapeutics, which includes recommendations for clinical trial design, adverse effect monitoring, and long-term safety assessments. The FDA's Breakthrough Therapy designation has also helped to expedite the development of new nucleic acid medicines.
According to the research report "Global Nucleic Acid and Oligonucleotide Therapeutics Market Overview, 2030 " published by Bonafide Research, the Global Nucleic Acid and Oligonucleotide Therapeutics market is anticipated to grow at more than 3.9% CAGR from 2024 to 2030. .The nucleic acid and oligonucleotide therapies market is distinguished by the existence of numerous major players who promote innovation and competition. Major pharmaceutical and biotechnology businesses, including Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Moderna, and BioNTech, are pioneering the development and commercialisation of nucleic acid-based treatments. These companies have made considerable investments in R&D, resulting in the launch of new therapies and technological advances. Recent market advances include the development of sophisticated RNAi therapeutics, which are intended to quiet specific disease-associated genes. For example, Alnylam Pharmaceuticals' Onpattro (patisiran) is a ground-breaking RNAi therapy approved to treat hereditary transthyretin-mediated amyloidosis. Similarly, Moderna and BioNTech have acquired popularity for their mRNA-based vaccinations, which show significant efficacy in preventing illnesses. Another major achievement is the development of antisense oligonucleotides, which are intended to regulate gene expression by targeting certain mRNA sequences. Ionis Pharmaceuticals has created many antisense treatments, including Spinraza (nusinersen), which treats spinal muscular atrophy. The effectiveness of these medicines demonstrates the promise for oligonucleotide-based treatments to treat a wide range of genetic illnesses.
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamics
Market Drivers
Technological Advancements: Significant advances in genomics, molecular biology, and biotechnology are propelling the development of nucleic acid and oligonucleotide therapies. Advancements in RNA sequencing, CRISPR/Cas9 gene editing, and better delivery technologies have increased the possibility of nucleic acid-based therapeutics.
Growing Prevalence of Genetic Disorders: The rising prevalence of genetic and uncommon disorders, such as cystic fibrosis, muscular dystrophy, and inherited malignancies, is driving need for targeted medicines. Nucleic acid-based treatments have the potential to alleviate many problems by addressing the underlying genetic causes.
Market Challenges
Delivery Mechanisms: Developing effective delivery systems for nucleic acid and oligonucleotide medicines is a major challenge. Ensuring that nucleic acids reach their target cells or tissues without degradation or off-target effects is critical for therapeutic success.
Cost and Affordability: The high cost of researching and producing nucleic acid-based medicines, combined with their complex manufacturing methods, can limit affordability and accessibility. This presents obstacles for wider adoption, particularly in low-resource areas.
Regulatory hurdles: Navigating the regulatory landscape for nucleic acid-based medicines can be challenging and time-consuming. Meeting the demanding standards for clinical trials, safety evaluations, and post-market surveillance can provide major obstacles for businesses.
Market Trends
Expanding Therapeutic Applications: The use of nucleic acid and oligonucleotide treatments is expanding beyond genetic illnesses and cancer to include cardiovascular ailments, metabolic disorders, and neurological problems. This increase indicates the increasing adaptability and potential of these treatments.
Advances in Delivery Technologies: Researchers are working on novel delivery techniques to improve the efficacy and safety of nucleic acid-based medicines. Nanoparticles, lipid nanoparticles, and viral vectors are being investigated to improve targeted delivery while reducing off-target effects.
Segmentation Analysis
Based on the report, the type is segmented into Antisense Oligonucleotides (ASO), siRNA, mRNA.
Among them, the mRNA segment is now leading due to its successful use in COVID-19 vaccines, which proved great efficacy and safety, attracting substantial investment and attention. The quick development capabilities of mRNA, as well as its ability to treat a wide range of ailments, contribute to its market leadership. Furthermore, the versatility and scalability of mRNA's manufacturing techniques contribute to its significance when contrasted to ASOs and siRNA, which, while important, have more limited applications and confront more complex delivery challenges. mRNA therapies, as demonstrated by the effectiveness of COVID-19 vaccines, employ mRNA to direct cells to create proteins that can activate an immune response or rectify disease-causing protein shortages. Antisense Oligonucleotides (ASOs) are designed to bind to specific mRNA regions and modulate gene expression by encouraging mRNA breakdown or inhibiting translation. This method is especially helpful in treating genetic diseases and certain malignancies. Notable examples are Spinraza (nusinersen) for spinal muscular atrophy and Onpattro (patisiran) for hereditary transthyretin-mediated amyloidosis. siRNA works by RNA interference, which causes the breakdown of complementary mRNA, effectively silencing certain genes. siRNA-based therapeutics target and downregulate genes linked to illnesses like viral infections and cancer.
Based on the report, the application is segmented into Neuromuscular Diseases, hATTR, COVID-19, Other.
In the worldwide nucleic acid and oligonucleotide therapies market, distinct therapeutic segments address a wide range of ailments, including neuromuscular diseases, hereditary transthyretin amyloidosis (hATTR), COVID-19, and others. Antisense oligonucleotides (ASOs), such as Spinraza (nusinersen), are used to treat neuromuscular illnesses such spinal muscular atrophy (SMA). These medicines work by adjusting gene expression to compensate for the faulty genes that cause muscle degeneration, which represents a huge step forward in managing these severe illnesses. RNA-based medicines such as Onpattro (patisiran) and Tegsedi (inotersen) efficiently treat hereditary transthyretin amyloidosis (hATTR), a rare and progressive disease characterised by the buildup of misfolded transthyretin protein. These treatments use RNA interference (RNAi) to limit mutant protein production. The COVID-19 pandemic has underlined the importance of nucleic acid therapies, including mRNA vaccines created by Pfizer-BioNTech and Moderna. These vaccines use mRNA to direct cells to generate a protein that causes an immune response to the SARS-CoV-2 virus. Because of the rapid development and excellent efficiency of these vaccinations, mRNA therapies have emerged as a market leader.
Regional Analysis
The Asia-Pacific region is leading the global market for nucleic acid and oligonucleotide therapeutics due to a combination of robust investment in biotechnology and significant advancements in research.
Asia-Pacific countries, particularly China, Japan, and South Korea, have emerged as dominant participants in the nucleic acid therapies industry. These countries have boosted their investment in biotechnology and life sciences, bolstered by government efforts and financial programs targeted at fostering innovation and development in this field. China, for example, has created national initiatives such as "Made in China 2025" to promote the development of biopharmaceuticals and cutting-edge technology, including nucleic acid-based medicines. Innovation and Research: The region is at the forefront of various ground-breaking advances in nucleic acid therapies. In China, advances in CRISPR/Cas9 gene editing and RNAi technologies have resulted in the creation of new treatment candidates.
Key Development
• In April 2024, the FDA designated a new siRNA treatment for a rare eye illness as a breakthrough therapy. This designation is intended to speed the development and review of new medicines with considerable potential benefits.
• In March 2024, Takeda Pharmaceutical launches ASO therapy in Japan.
Takeda Pharmaceutical has introduced a new ASO therapy in Japan to treat a specific type of genetic disease. This launch represents a big step forward in the availability of ASO treatments in the Asian market.
• In February 2024, BioNTech launched a global clinical trial for a novel mRNA-based vaccine addressing various infectious illnesses. This trial demonstrates the company's commitment to broadening the use of mRNA technology beyond COVID-19.
Table of Contents
- 1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats
- 2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Nucleic Acid and Oligonucleotide Therapeutics Market Size 2019-2030
- 2.1.2 Nucleic Acid and Oligonucleotide Therapeutics Market Size CAGR by Region (2019 VS 2023 VS 2030)
- 2.1.3 World Current & Future Analysis for Nucleic Acid and Oligonucleotide Therapeutics by Country/Region, 2019, 2023 & 2030
- 2.2 Nucleic Acid and Oligonucleotide Therapeutics Segment by Type
- 2.2.1 Antisense Oligonucleotides (ASO)
- 2.2.2 siRNA
- 2.2.3 mRNA
- 2.3 Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type
- 2.3.1 Nucleic Acid and Oligonucleotide Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
- 2.3.2 Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Type (2019-2024)
- 2.4 Nucleic Acid and Oligonucleotide Therapeutics Segment by Application
- 2.4.1 Neuromuscular Diseases
- 2.4.2 hATTR
- 2.4.3 COVID-19
- 2.4.4 Other
- 2.5 Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application
- 2.5.1 Nucleic Acid and Oligonucleotide Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
- 2.5.2 Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Application (2019-2024)
- 3 Nucleic Acid and Oligonucleotide Therapeutics Market Size by Player
- 3.1 Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Player
- 3.1.1 Global Nucleic Acid and Oligonucleotide Therapeutics Revenue by Player (2019-2024)
- 3.1.2 Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Player (2019-2024)
- 3.2 Global Nucleic Acid and Oligonucleotide Therapeutics Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
- 4 Nucleic Acid and Oligonucleotide Therapeutics by Region
- 4.1 Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2019-2024)
- 4.2 Global Nucleic Acid and Oligonucleotide Therapeutics Annual Revenue by Country/Region (2019-2024)
- 4.3 Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth (2019-2024)
- 4.4 APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth (2019-2024)
- 4.5 Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth (2019-2024)
- 4.6 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth (2019-2024)
- 5 Americas
- 5.1 Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2019-2024)
- 5.2 Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2019-2024)
- 5.3 Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2019-2024)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
- 6 APAC
- 6.1 APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2019-2024)
- 6.2 APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2019-2024)
- 6.3 APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2019-2024)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 7 Europe
- 7.1 Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2019-2024)
- 7.2 Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2019-2024)
- 7.3 Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2019-2024)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 8 Middle East & Africa
- 8.1 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics by Region (2019-2024)
- 8.2 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2019-2024)
- 8.3 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2019-2024)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
- 9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
- 10 Global Nucleic Acid and Oligonucleotide Therapeutics Market Forecast
- 10.1 Global Nucleic Acid and Oligonucleotide Therapeutics Forecast by Region (2025-2030)
- 10.1.1 Global Nucleic Acid and Oligonucleotide Therapeutics Forecast by Region (2025-2030)
- 10.1.2 Americas Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.1.3 APAC Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.1.4 Europe Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.1.5 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.2 Americas Nucleic Acid and Oligonucleotide Therapeutics Forecast by Country (2025-2030)
- 10.2.1 United States Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.2.2 Canada Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.2.3 Mexico Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.2.4 Brazil Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.3 APAC Nucleic Acid and Oligonucleotide Therapeutics Forecast by Region (2025-2030)
- 10.3.1 China Nucleic Acid and Oligonucleotide Therapeutics Market Forecast
- 10.3.2 Japan Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.3.3 Korea Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.3.4 Southeast Asia Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.3.5 India Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.3.6 Australia Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.4 Europe Nucleic Acid and Oligonucleotide Therapeutics Forecast by Country (2025-2030)
- 10.4.1 Germany Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.4.2 France Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.4.3 UK Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.4.4 Italy Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.4.5 Russia Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.5 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Forecast by Region (2025-2030)
- 10.5.1 Egypt Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.5.2 South Africa Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.5.3 Israel Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.5.4 Turkey Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 10.6 Global Nucleic Acid and Oligonucleotide Therapeutics Forecast by Type (2025-2030)
- 10.7 Global Nucleic Acid and Oligonucleotide Therapeutics Forecast by Application (2025-2030)
- 10.7.1 GCC Countries Market Nucleic Acid and Oligonucleotide Therapeutics Forecast
- 11 Key Players Analysis
- 11.1 Sarepta Therapeutics
- 11.1.1 Sarepta Therapeutics Company Information
- 11.1.2 Sarepta Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.1.3 Sarepta Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.1.4 Sarepta Therapeutics Main Business Overview
- 11.1.5 Sarepta Therapeutics Latest Developments
- 11.2 Ionis Pharmaceuticals
- 11.2.1 Ionis Pharmaceuticals Company Information
- 11.2.2 Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.2.3 Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.2.4 Ionis Pharmaceuticals Main Business Overview
- 11.2.5 Ionis Pharmaceuticals Latest Developments
- 11.3 Alnylam
- 11.3.1 Alnylam Company Information
- 11.3.2 Alnylam Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.3.3 Alnylam Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.3.4 Alnylam Main Business Overview
- 11.3.5 Alnylam Latest Developments
- 11.4 Biogen
- 11.4.1 Biogen Company Information
- 11.4.2 Biogen Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.4.3 Biogen Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.4.4 Biogen Main Business Overview
- 11.4.5 Biogen Latest Developments
- 11.5 Nippon Shinyaku
- 11.5.1 Nippon Shinyaku Company Information
- 11.5.2 Nippon Shinyaku Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.5.3 Nippon Shinyaku Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.5.4 Nippon Shinyaku Main Business Overview
- 11.5.5 Nippon Shinyaku Latest Developments
- 11.6 Sobi
- 11.6.1 Sobi Company Information
- 11.6.2 Sobi Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.6.3 Sobi Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.6.4 Sobi Main Business Overview
- 11.6.5 Sobi Latest Developments
- 11.7 Novartis
- 11.7.1 Novartis Company Information
- 11.7.2 Novartis Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.7.3 Novartis Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.7.4 Novartis Main Business Overview
- 11.7.5 Novartis Latest Developments
- 11.8 BioNTech
- 11.8.1 BioNTech Company Information
- 11.8.2 BioNTech Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.8.3 BioNTech Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.8.4 BioNTech Main Business Overview
- 11.8.5 BioNTech Latest Developments
- 11.9 Pfizer
- 11.9.1 Pfizer Company Information
- 11.9.2 Pfizer Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.9.3 Pfizer Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.9.4 Pfizer Main Business Overview
- 11.9.5 Pfizer Latest Developments
- 11.10 Moderna Therapeutics
- 11.10.1 Moderna Therapeutics Company Information
- 11.10.2 Moderna Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.10.3 Moderna Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.10.4 Moderna Therapeutics Main Business Overview
- 11.10.5 Moderna Therapeutics Latest Developments
- 11.11 Jazz Pharmaceuticals
- 11.11.1 Jazz Pharmaceuticals Company Information
- 11.11.2 Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.11.3 Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.11.4 Jazz Pharmaceuticals Main Business Overview
- 11.11.5 Jazz Pharmaceuticals Latest Developments
- 11.12 CureVac
- 11.12.1 CureVac Company Information
- 11.12.2 CureVac Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.12.3 CureVac Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.12.4 CureVac Main Business Overview
- 11.12.5 CureVac Latest Developments
- 11.13 Regulus Therapeutics
- 11.13.1 Regulus Therapeutics Company Information
- 11.13.2 Regulus Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.13.3 Regulus Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.13.4 Regulus Therapeutics Main Business Overview
- 11.13.5 Regulus Therapeutics Latest Developments
- 11.14 ProQR
- 11.14.1 ProQR Company Information
- 11.14.2 ProQR Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.14.3 ProQR Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.14.4 ProQR Main Business Overview
- 11.14.5 ProQR Latest Developments
- 11.15 Secarna
- 11.15.1 Secarna Company Information
- 11.15.2 Secarna Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.15.3 Secarna Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.15.4 Secarna Main Business Overview
- 11.15.5 Secarna Latest Developments
- 11.16 MiNA Therapeutics
- 11.16.1 MiNA Therapeutics Company Information
- 11.16.2 MiNA Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.16.3 MiNA Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.16.4 MiNA Therapeutics Main Business Overview
- 11.16.5 MiNA Therapeutics Latest Developments
- 11.17 Sylentis
- 11.17.1 Sylentis Company Information
- 11.17.2 Sylentis Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.17.3 Sylentis Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.17.4 Sylentis Main Business Overview
- 11.17.5 Sylentis Latest Developments
- 11.18 Arrowhead
- 11.18.1 Arrowhead Company Information
- 11.18.2 Arrowhead Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.18.3 Arrowhead Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.18.4 Arrowhead Main Business Overview
- 11.18.5 Arrowhead Latest Developments
- 11.19 Silence Therapeutics
- 11.19.1 Silence Therapeutics Company Information
- 11.19.2 Silence Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.19.3 Silence Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.19.4 Silence Therapeutics Main Business Overview
- 11.19.5 Silence Therapeutics Latest Developments
- 11.20 Dicerna
- 11.20.1 Dicerna Company Information
- 11.20.2 Dicerna Nucleic Acid and Oligonucleotide Therapeutics Product Offered
- 11.20.3 Dicerna Nucleic Acid and Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 11.20.4 Dicerna Main Business Overview
- 11.20.5 Dicerna Latest Developments
- 12 Research Findings and Conclusion
List of Tables
Table 1. Nucleic Acid and Oligonucleotide Therapeutics Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ millions)
Table 2. Nucleic Acid and Oligonucleotide Therapeutics Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Antisense Oligonucleotides (ASO)
Table 4. Major Players of siRNA
Table 5. Major Players of mRNA
Table 6. Nucleic Acid and Oligonucleotide Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ millions)
Table 7. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2019-2024) & ($ millions)
Table 8. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Type (2019-2024)
Table 9. Nucleic Acid and Oligonucleotide Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ millions)
Table 10. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2019-2024) & ($ millions)
Table 11. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Application (2019-2024)
Table 12. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue by Player (2019-2024) & ($ millions)
Table 13. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Player (2019-2024)
Table 14. Nucleic Acid and Oligonucleotide Therapeutics Key Players Head office and Products Offered
Table 15. Nucleic Acid and Oligonucleotide Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2019-2024) & ($ millions)
Table 19. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Region (2019-2024)
Table 20. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue by Country/Region (2019-2024) & ($ millions)
Table 21. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Country/Region (2019-2024)
Table 22. Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2019-2024) & ($ millions)
Table 23. Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Country (2019-2024)
Table 24. Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2019-2024) & ($ millions)
Table 25. Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Type (2019-2024)
Table 26. Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2019-2024) & ($ millions)
Table 27. Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Application (2019-2024)
Table 28. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2019-2024) & ($ millions)
Table 29. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Region (2019-2024)
Table 30. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2019-2024) & ($ millions)
Table 31. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2019-2024) & ($ millions)
Table 32. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2019-2024) & ($ millions)
Table 33. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Country (2019-2024)
Table 34. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2019-2024) & ($ millions)
Table 35. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2019-2024) & ($ millions)
Table 36. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2019-2024) & ($ millions)
Table 37. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2019-2024) & ($ millions)
Table 38. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2019-2024) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Nucleic Acid and Oligonucleotide Therapeutics
Table 40. Key Market Challenges & Risks of Nucleic Acid and Oligonucleotide Therapeutics
Table 41. Key Industry Trends of Nucleic Acid and Oligonucleotide Therapeutics
Table 42. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Forecast by Region (2025-2030) & ($ millions)
Table 43. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share Forecast by Region (2025-2030)
Table 44. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Forecast by Type (2025-2030) & ($ millions)
Table 45. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Forecast by Application (2025-2030) & ($ millions)
Table 46. Sarepta Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 47. Sarepta Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 48. Sarepta Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 49. Sarepta Therapeutics Main Business
Table 50. Sarepta Therapeutics Latest Developments
Table 51. Ionis Pharmaceuticals Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 52. Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 53. Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Ionis Pharmaceuticals Main Business
Table 55. Ionis Pharmaceuticals Latest Developments
Table 56. Alnylam Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 57. Alnylam Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 58. Alnylam Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 59. Alnylam Main Business
Table 60. Alnylam Latest Developments
Table 61. Biogen Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 62. Biogen Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 63. Biogen Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 64. Biogen Main Business
Table 65. Biogen Latest Developments
Table 66. Nippon Shinyaku Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 67. Nippon Shinyaku Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 68. Nippon Shinyaku Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 69. Nippon Shinyaku Main Business
Table 70. Nippon Shinyaku Latest Developments
Table 71. Sobi Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 72. Sobi Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 73. Sobi Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 74. Sobi Main Business
Table 75. Sobi Latest Developments
Table 76. Novartis Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 77. Novartis Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 78. Novartis Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 79. Novartis Main Business
Table 80. Novartis Latest Developments
Table 81. BioNTech Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 82. BioNTech Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 83. BioNTech Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 84. BioNTech Main Business
Table 85. BioNTech Latest Developments
Table 86. Pfizer Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 87. Pfizer Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 88. Pfizer Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 89. Pfizer Main Business
Table 90. Pfizer Latest Developments
Table 91. Moderna Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 92. Moderna Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 93. Moderna Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 94. Moderna Therapeutics Main Business
Table 95. Moderna Therapeutics Latest Developments
Table 96. Jazz Pharmaceuticals Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 97. Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 98. Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 99. Jazz Pharmaceuticals Main Business
Table 100. Jazz Pharmaceuticals Latest Developments
Table 101. CureVac Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 102. CureVac Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 103. CureVac Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 104. CureVac Main Business
Table 105. CureVac Latest Developments
Table 106. Regulus Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 107. Regulus Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 108. Regulus Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 109. Regulus Therapeutics Main Business
Table 110. Regulus Therapeutics Latest Developments
Table 111. ProQR Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 112. ProQR Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 113. ProQR Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 114. ProQR Main Business
Table 115. ProQR Latest Developments
Table 116. Secarna Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 117. Secarna Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 118. Secarna Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 119. Secarna Main Business
Table 120. Secarna Latest Developments
Table 121. MiNA Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 122. MiNA Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 123. MiNA Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 124. MiNA Therapeutics Main Business
Table 125. MiNA Therapeutics Latest Developments
Table 126. Sylentis Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 127. Sylentis Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 128. Sylentis Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 129. Sylentis Main Business
Table 130. Sylentis Latest Developments
Table 131. Arrowhead Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 132. Arrowhead Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 133. Arrowhead Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 134. Arrowhead Main Business
Table 135. Arrowhead Latest Developments
Table 136. Silence Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 137. Silence Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 138. Silence Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 139. Silence Therapeutics Main Business
Table 140. Silence Therapeutics Latest Developments
Table 141. Dicerna Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 142. Dicerna Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 143. Dicerna Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 144. Dicerna Main Business
Table 145. Dicerna Latest Developments
Table 1. Nucleic Acid and Oligonucleotide Therapeutics Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ millions)
Table 2. Nucleic Acid and Oligonucleotide Therapeutics Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Antisense Oligonucleotides (ASO)
Table 4. Major Players of siRNA
Table 5. Major Players of mRNA
Table 6. Nucleic Acid and Oligonucleotide Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ millions)
Table 7. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2019-2024) & ($ millions)
Table 8. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Type (2019-2024)
Table 9. Nucleic Acid and Oligonucleotide Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ millions)
Table 10. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2019-2024) & ($ millions)
Table 11. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Application (2019-2024)
Table 12. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue by Player (2019-2024) & ($ millions)
Table 13. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Player (2019-2024)
Table 14. Nucleic Acid and Oligonucleotide Therapeutics Key Players Head office and Products Offered
Table 15. Nucleic Acid and Oligonucleotide Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2019-2024) & ($ millions)
Table 19. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Region (2019-2024)
Table 20. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue by Country/Region (2019-2024) & ($ millions)
Table 21. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Country/Region (2019-2024)
Table 22. Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2019-2024) & ($ millions)
Table 23. Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Country (2019-2024)
Table 24. Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2019-2024) & ($ millions)
Table 25. Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Type (2019-2024)
Table 26. Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2019-2024) & ($ millions)
Table 27. Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Application (2019-2024)
Table 28. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2019-2024) & ($ millions)
Table 29. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Region (2019-2024)
Table 30. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2019-2024) & ($ millions)
Table 31. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2019-2024) & ($ millions)
Table 32. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2019-2024) & ($ millions)
Table 33. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Country (2019-2024)
Table 34. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2019-2024) & ($ millions)
Table 35. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2019-2024) & ($ millions)
Table 36. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2019-2024) & ($ millions)
Table 37. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2019-2024) & ($ millions)
Table 38. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2019-2024) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Nucleic Acid and Oligonucleotide Therapeutics
Table 40. Key Market Challenges & Risks of Nucleic Acid and Oligonucleotide Therapeutics
Table 41. Key Industry Trends of Nucleic Acid and Oligonucleotide Therapeutics
Table 42. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Forecast by Region (2025-2030) & ($ millions)
Table 43. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share Forecast by Region (2025-2030)
Table 44. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Forecast by Type (2025-2030) & ($ millions)
Table 45. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Forecast by Application (2025-2030) & ($ millions)
Table 46. Sarepta Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 47. Sarepta Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 48. Sarepta Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 49. Sarepta Therapeutics Main Business
Table 50. Sarepta Therapeutics Latest Developments
Table 51. Ionis Pharmaceuticals Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 52. Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 53. Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Ionis Pharmaceuticals Main Business
Table 55. Ionis Pharmaceuticals Latest Developments
Table 56. Alnylam Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 57. Alnylam Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 58. Alnylam Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 59. Alnylam Main Business
Table 60. Alnylam Latest Developments
Table 61. Biogen Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 62. Biogen Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 63. Biogen Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 64. Biogen Main Business
Table 65. Biogen Latest Developments
Table 66. Nippon Shinyaku Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 67. Nippon Shinyaku Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 68. Nippon Shinyaku Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 69. Nippon Shinyaku Main Business
Table 70. Nippon Shinyaku Latest Developments
Table 71. Sobi Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 72. Sobi Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 73. Sobi Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 74. Sobi Main Business
Table 75. Sobi Latest Developments
Table 76. Novartis Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 77. Novartis Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 78. Novartis Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 79. Novartis Main Business
Table 80. Novartis Latest Developments
Table 81. BioNTech Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 82. BioNTech Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 83. BioNTech Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 84. BioNTech Main Business
Table 85. BioNTech Latest Developments
Table 86. Pfizer Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 87. Pfizer Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 88. Pfizer Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 89. Pfizer Main Business
Table 90. Pfizer Latest Developments
Table 91. Moderna Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 92. Moderna Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 93. Moderna Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 94. Moderna Therapeutics Main Business
Table 95. Moderna Therapeutics Latest Developments
Table 96. Jazz Pharmaceuticals Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 97. Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 98. Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 99. Jazz Pharmaceuticals Main Business
Table 100. Jazz Pharmaceuticals Latest Developments
Table 101. CureVac Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 102. CureVac Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 103. CureVac Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 104. CureVac Main Business
Table 105. CureVac Latest Developments
Table 106. Regulus Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 107. Regulus Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 108. Regulus Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 109. Regulus Therapeutics Main Business
Table 110. Regulus Therapeutics Latest Developments
Table 111. ProQR Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 112. ProQR Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 113. ProQR Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 114. ProQR Main Business
Table 115. ProQR Latest Developments
Table 116. Secarna Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 117. Secarna Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 118. Secarna Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 119. Secarna Main Business
Table 120. Secarna Latest Developments
Table 121. MiNA Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 122. MiNA Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 123. MiNA Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 124. MiNA Therapeutics Main Business
Table 125. MiNA Therapeutics Latest Developments
Table 126. Sylentis Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 127. Sylentis Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 128. Sylentis Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 129. Sylentis Main Business
Table 130. Sylentis Latest Developments
Table 131. Arrowhead Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 132. Arrowhead Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 133. Arrowhead Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 134. Arrowhead Main Business
Table 135. Arrowhead Latest Developments
Table 136. Silence Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 137. Silence Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 138. Silence Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 139. Silence Therapeutics Main Business
Table 140. Silence Therapeutics Latest Developments
Table 141. Dicerna Details, Company Type, Nucleic Acid and Oligonucleotide Therapeutics Area Served and Its Competitors
Table 142. Dicerna Nucleic Acid and Oligonucleotide Therapeutics Product Offered
Table 143. Dicerna Nucleic Acid and Oligonucleotide Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 144. Dicerna Main Business
Table 145. Dicerna Latest Developments
List of Figures
Figure 1. Nucleic Acid and Oligonucleotide Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth Rate 2019-2030 ($ millions)
Figure 6. Nucleic Acid and Oligonucleotide Therapeutics Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Nucleic Acid and Oligonucleotide Therapeutics Sales Market Share by Country/Region (2023)
Figure 8. Nucleic Acid and Oligonucleotide Therapeutics Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Type in 2023
Figure 10. Nucleic Acid and Oligonucleotide Therapeutics in Neuromuscular Diseases
Figure 11. Global Nucleic Acid and Oligonucleotide Therapeutics Market: Neuromuscular Diseases (2019-2024) & ($ millions)
Figure 12. Nucleic Acid and Oligonucleotide Therapeutics in hATTR
Figure 13. Global Nucleic Acid and Oligonucleotide Therapeutics Market: hATTR (2019-2024) & ($ millions)
Figure 14. Nucleic Acid and Oligonucleotide Therapeutics in COVID-19
Figure 15. Global Nucleic Acid and Oligonucleotide Therapeutics Market: COVID-19 (2019-2024) & ($ millions)
Figure 16. Nucleic Acid and Oligonucleotide Therapeutics in Other
Figure 17. Global Nucleic Acid and Oligonucleotide Therapeutics Market: Other (2019-2024) & ($ millions)
Figure 18. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Application in 2023
Figure 19. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Player in 2023
Figure 20. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Region (2019-2024)
Figure 21. Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size 2019-2024 ($ millions)
Figure 22. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size 2019-2024 ($ millions)
Figure 23. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size 2019-2024 ($ millions)
Figure 24. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size 2019-2024 ($ millions)
Figure 25. Americas Nucleic Acid and Oligonucleotide Therapeutics Value Market Share by Country in 2023
Figure 26. United States Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 27. Canada Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 28. Mexico Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 29. Brazil Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 30. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Region in 2023
Figure 31. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Type (2019-2024)
Figure 32. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Application (2019-2024)
Figure 33. China Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 34. Japan Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 35. South Korea Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 36. Southeast Asia Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 37. India Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 38. Australia Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 39. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Country in 2023
Figure 40. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Type (2019-2024)
Figure 41. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Application (2019-2024)
Figure 42. Germany Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 43. France Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 44. UK Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 45. Italy Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 46. Russia Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 47. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Region (2019-2024)
Figure 48. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Type (2019-2024)
Figure 49. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Application (2019-2024)
Figure 50. Egypt Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 51. South Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 52. Israel Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 53. Turkey Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 54. GCC Countries Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 55. Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 56. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 57. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 58. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 59. United States Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 60. Canada Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 61. Mexico Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 62. Brazil Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 63. China Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 64. Japan Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 65. Korea Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 66. Southeast Asia Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 67. India Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 68. Australia Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 69. Germany Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 70. France Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 71. UK Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 72. Italy Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 73. Russia Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 74. Egypt Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 75. South Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 76. Israel Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 77. Turkey Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 78. GCC Countries Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 79. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share Forecast by Type (2025-2030)
Figure 80. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share Forecast by Application (2025-2030)
Figure 1. Nucleic Acid and Oligonucleotide Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth Rate 2019-2030 ($ millions)
Figure 6. Nucleic Acid and Oligonucleotide Therapeutics Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Nucleic Acid and Oligonucleotide Therapeutics Sales Market Share by Country/Region (2023)
Figure 8. Nucleic Acid and Oligonucleotide Therapeutics Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Type in 2023
Figure 10. Nucleic Acid and Oligonucleotide Therapeutics in Neuromuscular Diseases
Figure 11. Global Nucleic Acid and Oligonucleotide Therapeutics Market: Neuromuscular Diseases (2019-2024) & ($ millions)
Figure 12. Nucleic Acid and Oligonucleotide Therapeutics in hATTR
Figure 13. Global Nucleic Acid and Oligonucleotide Therapeutics Market: hATTR (2019-2024) & ($ millions)
Figure 14. Nucleic Acid and Oligonucleotide Therapeutics in COVID-19
Figure 15. Global Nucleic Acid and Oligonucleotide Therapeutics Market: COVID-19 (2019-2024) & ($ millions)
Figure 16. Nucleic Acid and Oligonucleotide Therapeutics in Other
Figure 17. Global Nucleic Acid and Oligonucleotide Therapeutics Market: Other (2019-2024) & ($ millions)
Figure 18. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Application in 2023
Figure 19. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Player in 2023
Figure 20. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Region (2019-2024)
Figure 21. Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size 2019-2024 ($ millions)
Figure 22. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size 2019-2024 ($ millions)
Figure 23. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size 2019-2024 ($ millions)
Figure 24. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size 2019-2024 ($ millions)
Figure 25. Americas Nucleic Acid and Oligonucleotide Therapeutics Value Market Share by Country in 2023
Figure 26. United States Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 27. Canada Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 28. Mexico Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 29. Brazil Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 30. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Region in 2023
Figure 31. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Type (2019-2024)
Figure 32. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Application (2019-2024)
Figure 33. China Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 34. Japan Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 35. South Korea Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 36. Southeast Asia Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 37. India Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 38. Australia Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 39. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Country in 2023
Figure 40. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Type (2019-2024)
Figure 41. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Application (2019-2024)
Figure 42. Germany Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 43. France Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 44. UK Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 45. Italy Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 46. Russia Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 47. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Region (2019-2024)
Figure 48. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Type (2019-2024)
Figure 49. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share by Application (2019-2024)
Figure 50. Egypt Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 51. South Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 52. Israel Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 53. Turkey Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 54. GCC Countries Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth 2019-2024 ($ millions)
Figure 55. Americas Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 56. APAC Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 57. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 58. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 59. United States Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 60. Canada Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 61. Mexico Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 62. Brazil Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 63. China Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 64. Japan Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 65. Korea Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 66. Southeast Asia Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 67. India Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 68. Australia Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 69. Germany Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 70. France Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 71. UK Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 72. Italy Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 73. Russia Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 74. Egypt Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 75. South Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 76. Israel Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 77. Turkey Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 78. GCC Countries Nucleic Acid and Oligonucleotide Therapeutics Market Size 2025-2030 ($ millions)
Figure 79. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share Forecast by Type (2025-2030)
Figure 80. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Market Share Forecast by Application (2025-2030)
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. Read More
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. Read More
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. Read More
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). Read More
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization.png "Nikita Jabrela")
Trusted Partners
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (01 May, 2025)
- Notify To Team (01 May, 2025)
- Report updation (02 May, 2025)
- Report Quality Check (02 May, 2025)
- Report Dispatch (03 May, 2025)
- Hard Copy
Recently Viewed Products
Global Nucleic Acid and Oligonucleotide Therapeutics Market Outlook , 2030
We are friendly and approachable, give us a call.